Cargando…
Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel
Taxanes, a group of cancer drugs that includes docetaxel and paclitaxel, have become a front-line therapy for a variety of metastatic cancers, but resistance can develop. There are several docetaxel resistance mechanisms in prostate cancer: unfavorable tumor microenvironment, drug efflux pump, alter...
Autor principal: | Kopczyńska, Ewa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731449/ https://www.ncbi.nlm.nih.gov/pubmed/26843836 http://dx.doi.org/10.5114/wo.2015.56648 |
Ejemplares similares
-
The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
por: Bascetta, Lorenzo, et al.
Publicado: (2017) -
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014) -
Role of MicroRNAs in Neuroendocrine Prostate Cancer
por: Sreekumar, Amritha, et al.
Publicado: (2022) -
The role of microRNAs in prostate cancer progression
por: Lo, U-Ging, et al.
Publicado: (2013) -
microRNAs and prostate cancer
por: Shi, Xu-Bao, et al.
Publicado: (2008)